CME Presentations

TROP2


Presentations


Speakers

  • Alexander Spira, MD, PhD, FACP

    Alexander Spira, MD, PhD, FACP

    Alexander Spira, MD, PhD, FACP

    Co-Chair, USOncology Thoracic Program

    Alexander Spira, MD, PhD, is the Director of the Virginia Cancer Specialists (VCS) Research Institute and the Phase I Trial Program, where he is actively involved in advancing medicine and offering targeted treatment options for patients. Also, he is a faculty member at Johns Hopkins School of Medicine serving as Assistant Professor of Oncology. For his research interests, Dr. Spira enjoys studying immunotherapy, personalized medicine, GI, thoracic and lung cancer and sarcomas. In addition, he is the Co-Chair of the USOncology Thoracic Oncology Committee, Chair of the USOncology Research Executive Committee, and member of the USOncology National Policy Board Executive Committee. In 2014, Dr. Spira received the prestigious “Castle Connolly America’s Top Doctor” award.
  • Aaron Lisberg, MD

    Aaron Lisberg, MD

    Aaron Lisberg, MD

    Assistant Professor of Clinical Medicine

    Aaron Lisberg, MD, is a medical oncologist and assistant professor of medicine at the David Geffen School of Medicine at University of California, Los Angeles (UCLA). He conducts translational research aimed at identifying novel therapeutic approaches for the treatment of thoracic malignancies and has experience as the principal investigator on multiple clinical trials in thoracic oncology. Dr Lisberg has published multiple peer-reviewed manuscripts and presented his research at numerous scientific meetings. He was the recipient of the prestigious LUNGevity Career Development Award in 2019 and recently found out that he has been awarded the American Cancer Society Clinical Scientist Development Grant, as well as a K08 Mentored Clinical Scientist Research Career Development Award.

CME Information

Future Directions in TROP2 Lung Cancer

Jointly provided by Postgraduate Institute for Medicine (PIM) and PlatformQ Health Education, LLC.

ACKNOWLEDGEMENT

This activity is supported by an educational grant from an educational grant from Daiichi Sankyo, Inc.

TUITION

Complimentary

JointlyAccreditedProvider Logo

JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

LIVE CREDIT DESIGNATION STATEMENTS

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours.

ENDURING CREDIT DESIGNATION STATEMENTS

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours.

DATE OF RELEASE/EXPIRATION

Live Activity

Tuesday, October 5, 2021, at 12:00-1:00pm EST

Enduring Material

October 5, 2021 – October 5, 2022.

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:
  • Assess the current data related to anti-TROP2 antibody-drug conjugates (ADCs) in lung cancer
  • Review clinical trials evaluating anti-TROP2 ADCs and patient eligibility criteria
  • Evaluate the practice implications of emerging TROP2 inhibitors
  • Review expert answers to clinical questions from oncology team members

TARGET AUDIENCE

The target audiences for this program are thoracic and medical oncologists, pulmonologists, pathologists, nurse practitioners (NPs), and other HCPs involved in the care of patients with lung cancer.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 1 hour to complete.

METHOD OF PARTICIPATION

There are no fees to participate in this activity. To participate in the activity, go to www.OMedLive.com. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

DISCLOSURE OF CONFLICTS OF INTEREST

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter Reported Financial Relationship
Aaron Lisberg, MD
Assistant Professor of Clinical Medicine
University of California, Los Angeles
Consulting Fees: AstraZeneca, Bristol-Myers Squibb, Eli-Lilly, Jazz Pharmaceuticals, Leica Biosystems, MorphoSys, Novartis, Novocure, Oncocyte, Pfizer
ontracted Research: AstraZeneca, Calithera Biosciences, Daiichi Sankyo, Dracen Pharmaceuticals, WindMIL
Ownership Interest less than 5%: Boston Scientific (wife)
Employment: Boston Scientific (wife)
Alexander Spira, MD, PhD
Director, Clinical Research
Co-Chair, USOncology Thoracic Program
NEXT Oncology VA
Virginia Cancer Specialists
Salary: Virginia Cancer Specialists
Consulting Fees: Incyte, Amgen, Novartis, Mirati Therapeutics, Gritstone Oncology, Jazz Pharmaceuticals, Takeda, Janssen Research and Development, Array BioPharma, AstraZeneca, Merck, Bristol-Myers Squibb
Contracted Research: LAM Therapeutics, Roche, AstraZeneca, Boehringer Ingelheim, Astellas Pharma,MedImmune, Novartis, Newlink Genetics, Incyte, Abbvie, Ignyta, Trovagene, Takeda, Macrogenics, CytomX Therapeutics, Astex Pharmaceuticals, Bristol-Myers Squibb, Loxo, Arch Therapeutics, Gritstone, Plexxikon, Amgen, Daiichi Sankyo, ADCT, Janssen Oncology, Mirati Therapeutics, Rubius
Ownership Interest greater than 5%: Eli Lilly

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
Tariqa Ackbarali
Medical Director
PlatformQ Health Education, LLC
None

The PIM planners and managers have nothing to disclose.

The following PlatformQ Health Education, LLC planner, Jaimee Harris-Gold, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support: Please contact the Postgraduate Institute for Medicine at inquiries@pimed.com.

Technical Support: For any technical issues or issues with your CME Certificate, please contact OMedLive.com at 1-877-394-1306 or at Support@OMedLive.com.